Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.69 |
| ▸ | MAP3K8 | P41279 | 7/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13505731 | 0.99 | EGFR (0.68) | EGFRERBB2MAP3K8SRC | |
| SCHEMBL3600034 | 0.91 | EGFR (0.72) | EGFRERBB2SRC | |
| SCHEMBL2574073 | 0.90 | EGFR (0.85) | EGFRERBB2SRC | |
| SCHEMBL14924278 | 0.90 | EGFR (0.73) | EGFRERBB2MAP3K8SRC | |
| Hydrochloric Acid SCHEMBL2052299 | 0.89 | EGFR (0.84) | EGFRERBB2SRC | |
| SCHEMBL1896455 | 0.88 | EGFR (0.85) | EGFRERBB2SRC | |
| Hydrochloric Acid SCHEMBL2843055 | 0.87 | EGFR (0.83) | EGFRERBB2SRC | |
| Hydrochloric Acid SCHEMBL2840495 | 0.87 | EGFR (0.83) | EGFRERBB2SRC | |
| SCHEMBL27728124 | 0.86 | EGFR (0.69) | EGFRERBB2MAP3K8SRC | |
| SCHEMBL27728120 | 0.85 | EGFR (0.71) | EGFRERBB2MAP3K8SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-2516403-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | Imperial Innovations Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077095-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011077095-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885MAP3K8 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.